Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.compbiomed.2021.104722 http://scihub22266oqcxt.onion/10.1016/j.compbiomed.2021.104722 34358995!ä!34358995 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Comput+Biol+Med 2021 ; 136 (ä): 104722 Nephropedia Template TP {{tp|p=34358995|t=2021. Drug repurposing of triazoles against mucormycosis using molecular docking: A short communication |pdf=|usr=}}{{34358995}} gab.com Text Drug repurposing of triazoles against mucormycosis using molecular docking: A short communication JO: Comput Biol Med http://www.kidney.de/pget.php?&tw=1&pmid=34358995 #FOAvip BACKGROUND: Mucormycosis, a fungal infection caused by Rhizopus species is on the rise in COVID-19 patients as a result of their suppressed immunity. The current therapies include systemic administration of Amphotericin B. HYPOTHESIS AND METHOD: We screened several triazole broad-spectrum antifungal agents against the therapeutic target in mucormycosis using computational techniques like molecular docking and compared them with isavuconazole, an approved drug. RESULT: The study concluded that 4 triazole drugs, pramiconazole, itraconazole, posaconazole and ketoconazole were strong candidates to be further evaluated and developed as a treatment for mucormycosis. CONCLUSION: Novel topical and oral therapies could be developed from these drug leads. Twit Text FOAVip Drug repurposing of triazoles against mucormycosis using molecular docking: A short communication ????Comput Biol Med http://www.kidney.de/pget.php?&tw=1&pmid=34358995 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34358995 #FOAvip English Wikipedia <ref>{{Cite pmid|34358995}}</ref> Drug repurposing of triazoles against mucormycosis using molecular docking: A short communication #MMPMID34358995 Mhatre S; Patravale V Comput Biol Med 2021[Sep]; 136 (ä): 104722 PMID34358995show ga BACKGROUND: Mucormycosis, a fungal infection caused by Rhizopus species is on the rise in COVID-19 patients as a result of their suppressed immunity. The current therapies include systemic administration of Amphotericin B. HYPOTHESIS AND METHOD: We screened several triazole broad-spectrum antifungal agents against the therapeutic target in mucormycosis using computational techniques like molecular docking and compared them with isavuconazole, an approved drug. RESULT: The study concluded that 4 triazole drugs, pramiconazole, itraconazole, posaconazole and ketoconazole were strong candidates to be further evaluated and developed as a treatment for mucormycosis. CONCLUSION: Novel topical and oral therapies could be developed from these drug leads. |*COVID-19[MESH] |*Mucormycosis/drug therapy[MESH] |Antifungal Agents/pharmacology/therapeutic use[MESH] |Drug Repositioning[MESH] |Humans[MESH] |Molecular Docking Simulation[MESH] |SARS-CoV-2[MESH]Drug repurposing of triazoles against mucormycosis using molecular doc(epmc).pdf DeepDyve Pubget Overpricing